Render Target: STATIC
Render Timestamp: 2024-12-03T12:05:41.376Z
Commit: cd2fae6ca3f811b1ddb1df24ac291ed56d5d501b
XML generation date: 2024-11-13 21:46:07.692
Product last modified at: 2024-12-02T17:15:14.103Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

FAM134B (E8Y9R) Rabbit mAb #83414

Filter:
  • WB
  • IP
  • IF

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 70
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:200
    Immunofluorescence (Immunocytochemistry) 1:200 - 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    FAM134B (E8Y9R) Rabbit mAb recognizes endogenous levels of total FAM134B protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro327 of human FAM134B protein.

    Background

    Family with sequence similarity 134, member B (FAM134B), also referred to as JK-1 and RETREG1, is a cis-Golgi endoplasmic reticulum (ER) transmembrane protein that plays a role in ER homeostasis and may contribute to several human diseases (1). FAM134B contains a conserved LC3-interacting domain (LIR) that facilitates binding to LC3 and GABARAP family members and targets impaired ER to the autophagosome for degradation by ER-phagy (2). Deletion of FAM134B leads to ER expansion and stress-induced apoptosis (2). Expression of FAM134B has been linked to a number of pathological conditions, including viral infection, cancer, and neuronal disorders (1). FAM134B can potentially inhibit viral infection, as demonstrated by studies of FAM134B knockouts that resulted in significantly higher rates of Ebola virus replication (3). Mutations in FAM134B that lead to an accumulation of misfolded proteins have also been associated with neuronal sensory disorders (2,4,5). The expression and mutational state of FAM134B can also have varying effects on cancer. The oncogenic effects of FAM134B were described in esophageal squamous carcinoma, whereas it appears to have tumor suppressor activity in colorectal cancer (6-8).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.